Adam Zayac
Hematology · New Brunswick, NJNPI 1023428273
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $477 of the $724 with a category attached, or 65.9%. It is spread thinly across 14 manufacturers, the largest accounting for just 18.2%. Reporting peaked in 2021 at $420 and has fallen 62.8% since, to $156 in 2022. That places this record below the midpoint for hematology clinicians in NJ, where the typical reported total is $2,217.
Across 26 payments — averaging $27.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$132
- Novartis$124
- TG Therapeutics, Inc.$120
- AstraZeneca$113
- Astellas Pharma US Inc$70
- Johnson & Johnson$49
- plus $116 from 8 others
What the payments were for
- Food & beverage$47766%
- Education$24734%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 2 | $132 |
| Novartis | 8 | $124 |
| TG Therapeutics, Inc. | 1 | $120 |
| AstraZeneca(2 entities) | 3 | $113 |
| Astellas Pharma US Inc | 1 | $70 |
| Johnson & Johnson(2 entities) | 3 | $49 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Pfizer | 1 | $15 |
| Incyte Corporation | 1 | $15 |
| Acrotech Biopharma Inc. | 1 | $15 |
| CTI Biopharma Corp. | 1 | $14 |
| Bristol Myers Squibb | 1 | $14 |
| Secura Bio, Inc. | 1 | $14 |
| ADC Therapeutics America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UKONIQ$120
How this compares
$724 in reported general payments places this provider in the 35th percentile of 43 hematology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VenclextaVenetoclax | 52 | $230,806 |
| Posaconazole | 11 | $10,750 |
| Azacitidine | 24 | $10,158 |
| Acyclovir | 26 | $339 |
| Levofloxacin | 18 | $224 |
| Prochlorperazine Maleate | 13 | $157 |
| Ondansetron Hcl | 17 | $122 |
Paid to pharmacies, not to this prescriber.
Other hematology in New Brunswick
- Mansi ShahNew Brunswick$131K
- Claire PhilippNew Brunswick$17K
- Joseph EidNew Brunswick$7K
- Ogechukwu EginiNew Brunswick$6K
- Xiaoyi ChenNew Brunswick$2K
- Payal SojitraNew Brunswick$186
- Virian SereiNew Brunswick$49
- Shelonitda RoseNew Brunswick$19
- Colleen CiccosantiNew Brunswick$14
- Ahmed GalalMorristown$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.